Veracyte is a pioneering global genomic diagnostics company dedicated to enhancing patient care through innovative solutions that provide crucial answers to clinical questions. By harnessing the latest advancements in genomic science and technology, Veracyte offers a diverse range of genomic tests aimed at improving diagnosis and treatment decisions for various cancers, including lung, prostate, breast, and thyroid, while also developing new tests for lymphoma subtyping and renal cancer. Headquartered in South San Francisco, California, the company prides itself on fostering an inclusive workforce and has earned recognition as a 2024 Certified™ Great Place to Work® in both the US and Israel, reflecting its commitment to employee satisfaction and engagement. Veracyte's mission is to help patients avoid unnecessary and invasive diagnostic procedures, ultimately accelerating their access to effective treatments.